Market research
SIOX Sio Gene Therapies Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 35M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- 0.0%
- Beta
- 1.08
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US8293991043
- Market cap
- 35M
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- 0.0%
- Beta
- 1.08
About
About Sio Gene Therapies Inc
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SIOX discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Sio Gene Therapies, Inc gets an overall score of 1/5.